Financial Performance Highlights
Windlas Biotech Limited reported strong financial results for FY26 with revenue from operations reaching ₹9,041 million, representing 19% YoY growth and marking the 13th consecutive quarter of record revenue performance. The company maintained robust profitability with adjusted EBITDA of ₹1,214 million (13.4% margin) and adjusted PAT of ₹831 million (9.2% margin). Cash flow generation remained strong with ₹1,049 million from operations, supporting a net liquidity position of ₹2,507 million and maintaining net debt-free status.
Operational Excellence
Business verticals showed consistent growth: Generic Formulations CDMO revenue grew 20% to ₹6,637 million, serving 926 customers and 5,644 brands with complex generics contributing 74% of CDMO revenue. Trade Generics & Institutional revenue increased 13% to ₹1,946 million, while Exports surged 40% to ₹458 million across 10 countries. Manufacturing capacity reached 8,522 million tablets & capsules annually with 66% utilization, while Plants 4 and 5 received Philippines GMP certification and Plant-6 achieved mechanical completion.
Corporate Actions & Capital Structure
The Board recommended a final dividend of ₹6.30 per share (record date July 16, 2026) and completed a ₹470 million buyback of 470,000 shares at ₹1,000 per share without promoter participation, reducing equity capital to 20,636,229 shares. The company implemented three ESOP schemes (2021, 2023, 2025) with 569,000 options outstanding and recognized ₹166.11 million in ESOP expenses, while maintaining promoter holding at 61.91%.
Financial Position & Investments
Total assets stood at ₹9,073.48 million with investments of ₹2,683.71 million and trade receivables of ₹2,274.01 million. The company maintained strong equity of ₹5,808.38 million with minimal borrowings of ₹298.75 million. R&D expenditure increased 32% to ₹83 million, supporting a portfolio of 4,393 complex generic products and innovative formulations including medicated chewing gums and sustained-release formulations.
Governance & Compliance
The company demonstrated full regulatory compliance with SEBI Listing Regulations and Companies Act, 2013, with no material pending litigations impacting financial position. Governance changes included the appointment of Dr. Tarashree Singhal as Additional Director and Independent Woman Director, while Mr. Srinivasan Venkataraman completed his tenure as Independent Director. The subsidiary Windlas Inc., USA was dissolved effective March 31, 2026.
Forward Outlook
The company maintains positive momentum with capacity expansion through Plant-6 commercialization expected in H1 FY27, continued focus on complex generics, and strong financial positioning to support future growth initiatives while managing risks including macroeconomic trends, regulatory changes, and competitive pressures.